Salvianolic-acid-B-Lithospermic-acid-B-DataSheet-生命科學試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemESalvianolicacidBCat.No.:HY-N1362CASNo.:121521-90-2Synonyms:LithospermicacidB分?式:C??H??O??分?量:718.61作?靶點:Autophagy作?通路:Autophagy儲存?式:Powder-20°C3years4°C2years*該產(chǎn)品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)?現(xiàn)配，即刻使?。溶解性數(shù)據(jù)體外實驗H2O:50mg/mL(69.58mM;ultrasonicandadjustpHto3withHCl)DMSO:25mg/mL(34.79mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM1.3916mL6.9579mL13.9158mL5mM0.2783mL1.3916mL2.7832mL10mM0.1392mL0.6958mL1.3916mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液；該產(chǎn)品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)?現(xiàn)配，即刻使?.體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.5mg/mL(3.48mM);Clearsolution1/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(3.48mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(3.48mM);Clearsolution4.請依序添加每種溶劑：PBSSolubility:50mg/mL(69.58mM);Clearsolution;NeedultrasonicBIOLOGICALACTIVITY?物活性SalvianolicacidB(LithospermicacidB)丹參的重組分，它常?來研究微循環(huán)疾病。體外研究SalvianolicacidB(SA-B)1and10micromol/LdecreasethecellactiveTGF-beta1secretionby63.3%and15.6%ofthecontrol,down-regulatpro-collgenalpha1(I)mRNAexpressionto77.0%and51.8%respectively(P[3]ThedegradationofSalvianolicacidBistemperaturedependent.Itwasstableat4oCfor30hinaqueoussolution.However,decompositionofSalvianolicacidBaqueoussolutionoccurresautomaticallyat25oC,andisenhancedat37,65and100oC.Ontheotherhand,SalvianolicacidBisalsostableat4,25and37oCfor30hinTPA(totalphenolicacids).[4]SalvianolicacidBisstablefor30hinbufferedphosphateaqueoussolutionsatpH1.5,3.0and5.0.WithanincreaseofpHfromtheneutral,thestabilityofSalBdecreased.[4]體內(nèi)研究SalvianolicacidB(SalB)(5mg·kg-1·h-1)significantlyattenuatesLPS-inducedpulmonarymicrocirculatorydisturbance,includingtheincreaseinleukocyteadhesionandalbuminleakage.Inaddition,LPSincreasespulmonarytissuewet-to-dryweightratioandtumornecrosisfactor[alpha]andinterleukin8levelsinplasmaandbronchoalveolarlavagefluidenhancestheexpressionofE-selectin,intercellularadhesionmolecule1,myeloperoxidase,MMP-2,andMMP-9,whereasitdecreasestheexpressionofAQP-1andAQP-5inpulmonarytissue,allofwhichareattenuatedbySalBpretreatment[1].SalBadministration(10mg/kg)significantlyamelioratetheAβ25-35peptide-inducedmemoryimpairmentinthepassiveavoidancetask(P[2].戶使?本產(chǎn)品發(fā)表的科研?獻?OxidMedCellLongev.2020Jul1;2020:1605456.?Phytomedicine.2019May;58:152754.?Pharmaceuticals.2022,15(2),179.?BiochemBiophysResCommun.2020Jun4;526(3):733-737.?Bioengineered.2022Feb;13(2):3486-3502.Seemorecustomervalidationsonwww.MedChemEREFERENCES2/3MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemE[1].LeeYW,etal.NeuroprotectiveeffectsofsalvianolicacidBonanAβ25-35peptide-inducedmousemodelofAlzheimer'sdisease.EurJPharmacol.2013Mar15;704(1-3):70-7.[2].LiuP,etal.EffectofsalvianolicacidBoncollagenproductionandmitogen-activatedproteinkinaseactivityinrathepaticstellatecells.ActaPharmacolSin.2002Aug;23(8):733-8.[3].Lin,Fang,etal.SalvianolicacidBprotectsfrompulmonarymicrocirculationdisturbanceinducedbylipopolysaccharideinrat.Shock.2013Mar;39(3):317-25.[4].ManXu,etal.AnalysisontheStabilityofTotalPhenolicAcidsandSalvianolicAcidBfromSalviamiltiorrhizabyHPLCandHPLC-MSn.NaturalProductCommunications.2008Vol.3,No.5,669-676.McePdfHeightCaut